CAS: 348-61-8; 1-Bromo-3,4-Difluorobenzene

上下游产品

CAS号109-01-3 N-甲基哌嗪 | CAS号60810-79-9 7,8-difluoro-10... | CAS号110-16-7 马来酸 | CAS号367-11-3 邻二氟苯 | CAS号455-86-7 3,4-二氟苯甲酸 | CAS号34036-07-2 3,4-二氟苯甲醛 | CAS号182192-98-9 bis-(3,4-difluo... | CAS号360576-04-1 6-溴-2,3-二氟苯甲醛 | CAS号60811-24-7 3,4－二氟苯硫酚 | CAS号60811-25-8 4-[(3,4-difluor... | CAS号367-11-3 邻二氟苯 | CAS号90897-92-0 3,4-二氟苯基溴化镁 | CAS号85312-59-0 3,4-二氟-4'-(反式-4... | CAS号844878-99-5 4-溴-3,4-二氟苯甲酮

1,2-二氟苯置于iron(III) Chloride,溴体系中,用 氯仿 用作溶剂,化学反应 5.0H,以79%的收率获得3,4-二氟溴苯
参考文献:使用四氟乙烯和丁-1,3-二烯作为起始构件的三步区域选择性合成 2,3-二氟卤代苯
标题:使用四氟乙烯和丁-1,3-二烯作为起始构件的三步区域选择性合成 2,3-二氟卤代苯
摘要:四氟乙烯和丁-1,3-二烯在流管反应器中在490-510oc下气相共解得到3,3,4,4-四氟环己-1-烯,它被选择性地转化为1-溴-或 1-氯-2,3-二氟苯通过中间卤化和脱卤化氢步骤.
Doi:10.1007/s11172-021-3168-5

专利信息

专利号:WO-2004058727-A1
优先权日:2002-12-20
标题 :Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
发明人：CHEN YUANWEI; O'CONNOR STEPHEN JAMES; GUNN DAVID; NEWCOM JASON; CHEN JIANQING; YI LIN; ZHANG HAI-JUN; HUNYADI LASZLO MATYAS; NATERO REINA
权利人:BAYER PHARMACEUTICALS CORP; CHEN YUANWEI; O'CONNOR STEPHEN JAMES; GUNN DAVID; NEWCOM JASON; CHEN JIANQING; YI LIN; ZHANG HAI-JUN; HUNYADI LASZLO MATYAS; NATERO REINA
摘要:This invention relates to substituted 3,5-dihydro-4H-imidazol-4-ones compounds which are useful in the treatment of obesity and obesity-related disorders, and as weight-loss and weight-control agents. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

专利号:US-6326372-B1
优先权日:1999-09-30
标 题:Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
发明人：EVANS BEN E; GILBERT KEVIN F
权利人:MERCK & CO INC
摘要:Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-6358959-B1
优先权日:1999-01-26
标 题:Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
发明人：BOCK MARK G; PATANE MICHAEL A; STEELE THOMAS G
权利人:MERCK & CO INC
摘要:Dihydro-polyazanaphthalen-2-one compounds (e.g., dihydroquinazolin-2-one and dihydropteridin-2-one derivatives) and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-6245773-B1
优先权日:1996-05-16
标题:5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
发明人：WONG WAI C; LAGU BHARAT; NAGARATHNAM DHANAPALAN; MARZABADI MOHAMMAD R; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to dihydropyrimidine compounds of the following formula: n which are selective antagonists for human α 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

专利号:US-6531471-B2
优先权日:1998-12-17
标 题:Morpholinone and morpholine derivatives and uses thereof
发明人：LAGU BHARAT; NAGARATHNAM DHANAPALAN; TIAN DAKE; GLUCHOWSKI CHARLES
权利人:SYNAPTIC PHARMA CORP
摘要:This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human α 1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the α 1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

专利号:US-6274583-B1
优先权日:1995-06-07
标题:Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C
权利人:MERCK & CO INC
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.